Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
109 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H1 2016', provides in depth analysis on Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - The report reviews Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) Overview 9 Therapeutics Development 10 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Products under Development by Stage of Development 10 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Products under Development by Therapy Area 11 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Products under Development by Indication 12 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Products Glance 14 Late Stage Products 14 Early Stage Products 15 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Products under Development by Companies 16 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Products under Development by Universities/Institutes 21 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Therapeutics Assessment 23 Assessment by Monotherapy/Combination Products 23 Assessment by Mechanism of Action 24 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 29 AstraZeneca Plc 29 AVEO Pharmaceuticals, Inc. 30 Daiichi Sankyo Company, Limited 31 Etubics Corporation 32 F. Hoffmann-La Roche Ltd. 33 GamaMabs Pharma S.A. 34 GlaxoSmithKline Plc 35 Hanmi Pharmaceuticals, Co. Ltd. 36 ImmunoGen, Inc. 37 Kolltan Pharmaceuticals, Inc. 38 Merrimack Pharmaceuticals, Inc. 39 Merus B.V. 40 Novartis AG 41 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 42 Sihuan Pharmaceutical Holdings Group Ltd. 43 Sorrento Therapeutics, Inc. 44 Symphogen A/S 45 Takis S.r.l. 46 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Drug Profiles 47 AV-203 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 AV-353 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 BA-0702 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 elgemtumab - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 ETBX-031 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 FCN-411 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 GSK-2849330 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 H4B-121 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 huHER3-8 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 KTN-3379 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 lumretuzumab - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 MCLA-125 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 MM-141 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Monoclonal Antibodies to Antagonize HER-3 for Breast and Pancrestic Cancers - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 patritumab - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 pirotinib - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 poziotinib - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 sapitinib - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 seribantumab - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 sirotinib - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 Sym-013 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 TK-003 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 Vaccine to Target HER1, HER2 and HER3 for Cancer - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Dormant Projects 88 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Discontinued Products 91 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Featured News & Press Releases 94 Jun 06, 2016: Kolltan Pharmaceuticals Presents Clinical Data for KTN3379 in an Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 94 May 31, 2016: Daiichi Sankyo Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer 96 May 18, 2016: Merrimack to Present Data on Seribantumab at the 2016 American Society of Clinical Oncology Annual Meeting 96 May 18, 2016: Kolltan Pharmaceuticals to Report KTN3379 Clinical Data in an Oral Presentation at the Upcoming 2016 American Society of Clinical Oncology Annual Meeting 97 May 17, 2016: Merrimack Presents Expanded Analysis from Seribantumab (MM-121) Phase 2 Breast Cancer Study at the AACR Precision Medicine Series 98 May 02, 2016: AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor Antibody for PAH 99 Apr 20, 2016: Kolltan Pharmaceuticals Presents Preclinical Data on KTN3379 at the 2016 American Association for Cancer Research Annual Meeting 99 Mar 16, 2016: Merrimack to Present on MM-141 (istiratumab) at the 2016 American Association for Cancer Research Annual Meeting 101 Mar 07, 2016: Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor 101 Dec 22, 2015: Merrimack Amends MM-121 Phase 2 Clinical Study in Heregulin-Positive Non-Small Cell Lung Cancer to Support Potential Registration 102 Dec 08, 2015: Spectrum Pharmaceuticals Highlights Abstracts on Poziotinib at the San Antonio Breast Cancer Symposium 102 Nov 20, 2015: Spectrum Pharmaceuticals Submits Phase 2 Breast Cancer Protocol to FDA as Part of an Investigational New Drug Application for Poziotinib 103 Nov 06, 2015: Kolltan Pharmaceuticals Presents KTN3379 Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 104 Oct 30, 2015: Kolltan To Present Preclinical Data on KTN3379 at the AACR-NCI-EORTC International Conference 105 Oct 16, 2015: Kolltan Pharmaceuticals Announces Interim Efficacy Data from KTN3379 Phase 1b Clinical Trial 105 Appendix 108 Methodology 108 Coverage 108 Secondary Research 108 Primary Research 108 Expert Panel Validation 108 Contact Us 108 Disclaimer 109
List of Tables
Number of Products under Development for, H1 2016 10 Number of Products under Development by Therapy Area, H1 2016 11 Number of Products under Development by Indication, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Early Stage Products, H1 2016 15 Number of Products under Development by Companies, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Development by Companies, H1 2016 (Contd..1) 18 Products under Development by Companies, H1 2016 (Contd..2) 19 Products under Development by Companies, H1 2016 (Contd..3) 20 Number of Products under Investigation by Universities/Institutes, H1 2016 21 Products under Investigation by Universities/Institutes, H1 2016 22 Assessment by Monotherapy/Combination Products, H1 2016 23 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 28 Pipeline by AstraZeneca Plc, H1 2016 29 Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 30 Pipeline by Daiichi Sankyo Company, Limited, H1 2016 31 Pipeline by Etubics Corporation, H1 2016 32 Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 33 Pipeline by GamaMabs Pharma S.A., H1 2016 34 Pipeline by GlaxoSmithKline Plc, H1 2016 35 Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 36 Pipeline by ImmunoGen, Inc., H1 2016 37 Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016 38 Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 39 Pipeline by Merus B.V., H1 2016 40 Pipeline by Novartis AG, H1 2016 41 Pipeline by Shanghai Fosun Pharmaceutical (Group) Co., Ltd., H1 2016 42 Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 43 Pipeline by Sorrento Therapeutics, Inc., H1 2016 44 Pipeline by Symphogen A/S, H1 2016 45 Pipeline by Takis S.r.l., H1 2016 46 Dormant Projects, H1 2016 88 Dormant Projects (Contd..1), H1 2016 89 Dormant Projects (Contd..2), H1 2016 90 Discontinued Products, H1 2016 91 Discontinued Products (Contd..1), H1 2016 92 Discontinued Products (Contd..2), H1 2016 93
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
